MPG.eBooks - Search Results

1

Pharmacoeconomic review report: Inotersen (Tegsedi) (Akcea Therapeutics, Inc.) : indication : stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloido...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Read Now

2

Clinical review report: Inotersen (Tegsedi) (Akcea therapeutics, inc.) : indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATT...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... in adults with Hereditary transthyretin-mediated amyloidosis...”

Read Now

3

Clinical review report: Inotersen (Tegsedi) (Akcea therapeutics, inc.) : indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATT...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... in adults with Hereditary transthyretin-mediated amyloidosis...”

Read Now

4

Pharmacoeconomic review report: Inotersen (Tegsedi) (Akcea Therapeutics, Inc.) : indication : stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloido...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Read Now

5

CADTH Canadian drug expert committee recommendation: Inotersen (Tegsedi -- Akcea Therapeutics, Inc.) : indication : treatment of polyneuropathy in adults with hereditary transthyre...

Published 2019

Canadian Agency for Drugs and Technologies in Health

Read Now

6

CADTH Canadian drug expert committee recommendation: Inotersen (Tegsedi -- Akcea Therapeutics, Inc.) : indication : treatment of polyneuropathy in adults with hereditary transthyre...

Published 2019

Canadian Agency for Drugs and Technologies in Health

Read Now

7

CADTH Canadian drug expert committee recommendation: Patisiran (Onpattro -- Alnylam Netherlands BV) : indication : for the treatment of polyneuropathy in adult patients with heredi...

Published 2019

Canadian Agency for Drugs and Technologies in Health

Read Now

8

CADTH Canadian drug expert committee recommendation: Patisiran (Onpattro -- Alnylam Netherlands BV) : indication : for the treatment of polyneuropathy in adult patients with heredi...

Published 2019

Canadian Agency for Drugs and Technologies in Health

Read Now

9

Pharmacoeconomic review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloid...

Published 2020

CADTH

Read Now

10

Pharmacoeconomic review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloid...

Published 2020

CADTH

Read Now

11

Clinical review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wi...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“...-type or hereditary transthyretin-mediated amyloidosis (hATTR)...”

Read Now

12

Clinical review report: Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wi...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“...-type or hereditary transthyretin-mediated amyloidosis (hATTR)...”

Read Now

13

Cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors : a review of the clinical evidence

Published 2015

Canadian Agency for Drugs and Technologies in Health

Read Now

14

Clinical review report: Patisiran (Onpattro) : (Alnylam Netherlands B.V.)

Published 2019

Canadian Agency for Drugs and Technologies in Health

“... effects of patisiran 2 mg/mL IV solution for the treatment of hereditary transthyretin-mediated...”

Read Now

15

Clinical review report: Patisiran (Onpattro) : (Alnylam Netherlands B.V.)

Published 2019

Canadian Agency for Drugs and Technologies in Health

“... effects of patisiran 2 mg/mL IV solution for the treatment of hereditary transthyretin-mediated...”

Read Now

16

Montelukast for sleep apnea : a review of the clinical effectiveness, cost effectiveness, and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

“...Leukotrienes are inflammatory mediators in the respiratory system and are involved...”

Read Now

17

Montelukast for sleep apnea : a review of the clinical effectiveness, cost effectiveness, and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

“...Leukotrienes are inflammatory mediators in the respiratory system and are involved...”

Read Now

18

Use of antipsychotics and/or benzodiazepines as rapid tranquilization in in-patients of mental facilities and emergency departments : a review of the clinical effectiveness and gui...

Published 2015

CADTH Rapid Response Service

“... to be effective in mediating the symptoms of agitation or aggression. Further, guidelines appeared to vary...”

Read Now

19

Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

“...The NMDA receptor mediates glutamate excitatory neurotransmission in the brain...”

Read Now

20

Use of antipsychotics and/or benzodiazepines as rapid tranquilization in in-patients of mental facilities and emergency departments : a review of the clinical effectiveness and gui...

Published 2015

CADTH Rapid Response Service

“... to be effective in mediating the symptoms of agitation or aggression. Further, guidelines appeared to vary...”

Narrow Search